The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V54762 | PSMA-ALB-56 | 2306049-48-7 | PSMA-ALB-56 is a PSMA-targeting radioligand composed of a glutamate-urea PSMA-binding entity and an albumin conjugate. |
|
V54778 | PSMA-Val-Cit-PAB-MMAE | 2748039-79-2 | PSMA-Val-Cit-PAB-MMAE is a new MMAE-based small molecule PSMA targeting conjugate for prostate cancer chemotherapy. |
|
V76165 | Rha-PEG3-SMCC | 2794904-62-2 | Rha-PEG3-SMCC (compound 13) is part of an antibody-reactive molecule conjugate consisting of the protein cross-linker SMCC and the non-degradable ADC linker Rha-PEG3. |
|
V54763 | SC-VC-PAB-DM1 | 2259318-47-1 | SC-VC-PAB-DM1 is part of an antibody-drug-conjugate/ADC with anti-cancer activity. |
|
V37473 | SC239 | 1977557-97-3 | SC239 is a cleavable 2-aminophenyl hemiasterin active molecular linker. |
|
V36681 | SG3199-Val-Ala-PAB | 1595275-61-8 | SG3199-Val-Ala-PAB is an intermediate in the synthesis/preparation of Tesirine. |
|
V4651 | SMCC-DM1 | 1228105-51-8 | SMCC-DM1 (DM1-SMCC) is DM1 (mertansine) with a reactive linker SMCC to synthesize antibody drug conjugate. |
|
V54755 | SN38-COOH | 2170118-23-5 | SN38-COOH may be utilized to prepare antibody-active molecule conjugates (ADC). |
|
V54783 | SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 | 1373170-36-5 | SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is an ADC drug-Linker conjugate. |
|
V52943 | SPB | 858128-57-1 | SPB is the active molecular linker of ADC. |
|
V32471 | SPDB-DM4 | 1626359-62-3 | SPDB-DM4 is a novel drug-linker conjugate used for the synthesis of antibody-drug-conjugate (ADC) with maytansine as the payload (DM4) which is connected to the antibody part via a SPDB linker, exhibiting potent anti-tumor activity. |
|
V54756 | SPP-DM1 | 452072-20-7 | SPP-DM1 is a part of the antibody-drug-conjugates/ADCs, which is connected by the microtubule-disrupting agent DM1 and the ADC linker SPP. |
|
V54793 | ST8154AA1 | 2247025-59-6 | ST8154AA1 is part of antibody-conjugated active molecules ADCs with HDAC inhibitor loads and linkers and has anti-tumor activity. |
|
V54771 | ST8155AA1 | 2247025-63-2 | ST8155AA1 is part of antibody-conjugated active molecules ADCs with HDAC inhibitor loads and linkers and has anti-tumor activity. |
|
V54766 | STING agonist-20-Ala-amide-PEG2-C2-NH2 | 2720500-49-0 | STING agonist-20-Ala-amide-PEG2-C2-NH2 is a scaffold containing a stimulator of interferon genes (STING). |
|
V76476 | STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA | STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is a scaffold containing a stimulator of interferon genes (STING). | |
|
V54769 | Sulfo-PDBA-DM4 | 1461704-01-7 | Sulfo-PDBA-DM4 is a drug-linker conjugate, which is connected by the linker Sulfo-PDBA and the toxic molecule DM4. |
|
V81479 | Sulfo-SPDB-DGN462 | Sulfo-SPDB-DGN462 is an active molecular linker conjugate of ADC. | |
|
V52448 | SuO-Glu-Val-Cit-PAB-MMAE | 1895916-24-1 | SuO-Glu-Val-Cit-PAB-MMAE is made up of cleavable ADC (Antibody-drug conjugate) linker (SuO-Glu-Val-Cit-PAB) and MMAE, which is an effective microtubule (tubulin) inhibitor. |
|
V76466 | SuO-Val-Cit-PAB-MMAE | SuO-Val-Cit-PAB-MMAE is part of the antibody conjugate active molecule (drug-linker conjugate for ADC). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
